Application of mRNA for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
1. A method of stimulating an antitumor immune response in a subject comprising administering an effective amount of a cell-free composition comprising mRNA encoding an PSA antigen to a subject in need thereof, thereby stimulating a T-cell mediated cytotoxic anticancer immune response in the subject.
2. The method of claim 1 , wherein the subject has a cancer.
3. The method of claim 2 , wherein the cancer is a prostate cancer.
4. The method of claim 1 , wherein the composition comprises mRNA encoding at least 2, 3, 4 or 5 different tumor antigens.
5. The method of claim 1 , wherein the method further comprises administering at least 2, 3, 4 or 5 different cell-free compositions comprising mRNA encoding different tumor antigens to the subject.
6. The method of claim 1 , wherein the mRNA is complexed with at least one cationic or polycationic agent.
7. The method of claim 6 , wherein the cationic or polycationic agent is chosen from the group consisting of protamine, poly-L-lysine, poly-L-arginine and histones.
8. The method of claim 7 , wherein the mRNA is complexed with protamine.
9. The method of claim 1 , further comprising administering one or more adjuvant(s) to the subject.
10. The method of claim 9 , wherein the adjuvant is chosen from the group consisting of lipopolysaccharide, TNF-α, CD40 ligand, GP96, oligonucleotides with a CpG motif, aluminum hydroxide, Freund's adjuvant, a lipopeptide and a cytokine.
11. The method of claim 10 , wherein the cytokine is GM-CSF.
12. The method of claim 1 , wherein the mRNA encoding the antigen has a different nucleic acid sequence compared with the wild-type mRNA encoding the antigen.
13. The method of claim 1 , wherein the mRNA comprises a 5′ cap structure, at least one IRES and/or a poly(A + ) tail of at least 25 nucleotides.
14. The method of claim 13 , wherein the mRNA comprises a 5′ cap structure and a poly(A + ) tail of at least 25 nucleotides.
15. The method of claim 1 , wherein the mRNA comprises at least one 5′-stabilizing sequence and/or at least one 3′-stabilizing sequence.
16. The method of claim 15 , wherein the 5′- and/or the 3′-stabilizing sequence(s) is/are chosen from the group consisting of untranslated sequences (UTR) of the β-globin gene and a stabilizing sequence of the general formula (C/U)CCAN x CCC(U/A)Py x UC(C/U)CC.
17. The method of claim 1 , wherein the mRNA comprises at least one analog of naturally occurring nucleotide selected from the group consisting of phoshorothioates, phosphoroamidates, peptide nucleotides, methylphosphates, 7-deazaguanosine, 5-methylcytosine and inosine.
18. The method of claim 1 , wherein the cell-free composition comprising mRNA is administered by injection of an aqueous solution comprising the mRNA.
19. The method of claim 1 , wherein the cell-free composition comprising mRNA is administered intradermally.
20. The method of claim 1 , wherein the cell-free composition comprising mRNA is administered two or more times.